TIDMMXF
RNS Number : 9739J
The MedicX Fund Limited
03 July 2017
For immediate release
3 July 2017
MedicX Fund Limited
("MedicX Fund", "the Fund" or "the Company")
Allotment of scrip shares to Directors
and Investment Adviser and total voting rights
Members of the Company's Board of Directors elected to
participate in the Company's scrip dividend scheme in respect of
the June 2017 dividend for the quarter ended 31 March 2017, and
accordingly acquired ordinary shares of no par value in the Company
(the "Shares") as disclosed in the table below.
Shares Total Percentage
Acquired Shares Holding
Held
David Staples
(Chairman) 1,573 96,369 0.022%
Shelagh Mason 526 32,249 0.008%
John Hearle 514 31,472 0.007%
Helen Mahy -(*) 28,604 0.007%
(*) Helen Mahy did not elect to participate in the scrip
dividend scheme in respect of the June 2017 dividend.
The Shares were acquired on 30 June 2017 and rank pari passu
with the Company's existing ordinary shares.
The Directors detailed above, who elected to participate in the
Company's scrip dividend scheme, did so under an election mandate
which remains in place until revoked.
Octopus Healthcare Adviser Ltd (the Company's Investment
Adviser) also elected to participate in the Company's scrip
dividend scheme in respect of the June 2017 dividend for the
quarter ended 31 March 2017, and accordingly was allotted 36,919
ordinary shares of no par value in the Company (the "Shares"). The
Shares were sold out of treasury at the previously advised scrip
calculation price of 90.3 pence per share.
The acquisition of the Shares brings Octopus Healthcare Adviser
Ltd's total holding in the Company to 2,259,489 shares,
representing 0.53% of the Company's total voting rights. The Shares
were acquired on 30 June 2017 and rank pari passu with the
Company's existing ordinary shares.
In accordance with the Financial Conduct Authority's Disclosure
and Transparency Rules, the total number of ordinary shares of the
Company in issue as at 30 June 2017 was 428,530,249 (excluding
treasury shares) with each share holding one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in the Company, under the Disclosure and Transparency Rules.
The Company also holds 7,472,150 ordinary shares in
treasury.
Copies of the documents relating to the Scrip Dividend
Alternative are available for inspection through the National
Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).
End
For further information please contact:
MedicX Fund +44 (0) 1481 723 450
David Staples, Chairman
Octopus Healthcare Group +44 (0) 20 3142 4820
Mike Adams, Chief Executive Officer
Buchanan +44 (0) 20 7466 5000
Charles Ryland/Vicky Hayns
Information on MedicX Fund Limited
MedicX Fund Limited ("MXF", "MedicX Fund", "the Fund" or "the
Company", or together with its subsidiaries, the "Group") is the
specialist primary care infrastructure investor in modern,
purpose-built primary healthcare properties in the United Kingdom
and Ireland, listed on the London Stock Exchange, with a portfolio
comprising 157 properties.
The Investment Adviser to the Company is Octopus Healthcare
Adviser Ltd, which is part of the Octopus Healthcare group. Octopus
Healthcare invests in and develops properties as well as creating
partnerships to deliver innovative healthcare buildings to improve
the health, wealth and wellbeing of the UK. It currently manages
over GBP1 billion of healthcare investments across a number of
platforms, with a focus on five core areas: GP surgeries, care
homes, special education schools, retirement housing and private
hospitals. Octopus Healthcare is part of the Octopus group, a
fast-growing UK fund management business with leading positions in
several specialist sectors including healthcare property, energy,
property finance and smaller company investing. Octopus manages
GBP6 billion of funds for more than 50,000 retail and institutional
investors.
Octopus Healthcare Adviser Ltd is authorised and regulated by
the Financial Conduct Authority.
The Company's website address is www.medicxfund.com. Neither the
contents of the Company's website nor the contents of any website
accessible from hyperlinks on the Company's website (or any other
website), nor the contents of any website accessible from
hyperlinks within this announcement, are incorporated into, or
forms part of, this announcement.
The Company's Legal Entity Identifier is
2138008POF35FTNFCB25
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGGNDFRGNZM
(END) Dow Jones Newswires
July 03, 2017 11:02 ET (15:02 GMT)
Medicx (LSE:MXF)
Historical Stock Chart
From Apr 2024 to May 2024
Medicx (LSE:MXF)
Historical Stock Chart
From May 2023 to May 2024